N/A N=13 Treatment

[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors

Brain Cancer · Gliomas

Bottom Line

View on ClinicalTrials.gov: NCT00832598 ↗

Enrolled (actual)

Serious AEs

30.8%

Results posted

Apr 2018

Primary outcome: Primary: Determine & Comp Biodistribution, Clearance, & Dosimetry of [18F]FACBC & [18F]FLT Tissue/Organs w/i the Field of View of the Dynamic PET Imag Studies prior-to & During Anti-AKT &/or Anti-VEGF Directed Therapies Alone or in Combin With Radia for Glioma.

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: [18F]FACBC PET and [18F]FLT PET imaging (Radiation)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Memorial Sloan Kettering Cancer Center
Primary completion: Mar 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Determine & Comp Biodistribution, Clearance, & Dosimetry of [18F]FACBC & [18F]FLT Tissue/Organs w/i the Field of View of the Dynamic PET Imag Studies prior-to & During Anti-AKT &/or Anti-VEGF Directed Therapies Alone or in Combin With Radia for Glioma.	—	—
SECONDARY Compare [18F]FACBC PET & [18F]FLT PET Results With MRI Imaging in Patients With Recurrent Gliomas (n=30).	—	—
SECONDARY Explore if [18F]FACBC PET and [18F]FLT PET Imaging Can be Related to Molecular Markers (AKT, VEGFR, and Related Signaling/Biologic Changes by Immunohistochemistry and/or Analysis of Flash Frozen Tissue)	—	—

Summary

The purpose of this study is to help us understand gliomas, one type of brain tumor. This research protocol makes pictures of gliomas. We will take pictures of the glioma before and after treatment. The pictures are made with a positron emission tomography (PET) scanner. PET scans use radioactive markers to "see" cancer cells. We plan to use two different radioactive markers, [18F]FACBC and [18F]FLT, to "see" if the glioma responds to the treatment being recommended by the doctor. We are investigating whether one or both of these types of PET scans can help us to better understand gliomas and their response to treatment. We expect these pictures will give us information the your tumor and may help us to understand why the treatment that the patient is receiving is affecting the tumor the way that it is. We also hope to collect information about the amount of radioactivity exposure. We will measure radioactivity exposure to the tumor, brain and other organs.

Eligibility Criteria

Inclusion Criteria

Registered patient at MSKCC.
Child-bearing age females must be non-pregnant, (documented by a negative pregnancy test within the last 2 weeks), non-lactating, and must be using adequate contraception or be surgically sterile.
Patients with gliomas
Patients planning to start anti-AKT and/or anti-VEGF directed therapies .
Patients with measurable disease on MRI or CT neuroimaging.

Exclusion Criteria

Patient is incontinent of urine or stool (which would make them unable to tolerate lying still for 60 minutes).
Patient cannot tolerate lying still for a 60 minute session in the PET tomograph.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00832598). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.